Too early to expect an "aha" moment for AI in drug development, says Leerink Partners
U.S. equity indexes red: Nasdaq off most, down ~1.3%
Cons disc weakest S&P sector; Real Estate leads gainers
Dollar up; gold down ~1%; crude down >1.5%; bitcoin off >2%
U.S. 10-Year Treasury yield edges up to ~4.23%
Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com
TOO EARLY TO EXPECT AN "AHA" MOMENT FOR AI IN DRUG DEVELOPMENT, SAYS LEERINK PARTNERS
The use-cases for artificial intelligence on the clinical development side remain early, although there is clear evidence of its use on the administrative side of healthcare, brokerage Leerink Partners said on Wednesday.
Although AI is finding its way into numerous pockets, it may be too early to expect an "aha" moment, Leerink analysts said, adding AI maybe more of an "enabling agent than a specific revenue driver."
Whether what companies are promising to do is likely exaggerated or what generative AI promises to achieve were by far the over-arching theme at a conference held in Las Vegas this week.
Drugmakers have been experimenting with artificial intelligence for years and have more recently used it to find patients for clinical trials quickly, or to reduce the number of people needed to test medicines, which not only accelerates the development process but also potentially saves dollars.
NVIDIA NVDA.O, the AI darling, noted that the various efforts around the use of medical devices utilization, clinical trial matching, and digital health applications were still early in process.
Leerink says rolling out more digital-health apps is feasible, as virtual care becomes more broadly ingrained within the traditional care setting.
(Sriparna Roy)
*****
FOR WEDNESDAY'S EARLIER LIVE MARKETS POSTS:
A 50 BASIS-POINT FED CUT THIS YEAR NOT OUT OF THE PICTURE JUST YET - CLICK HERE
DOUBLE SHOT, ON THE HOUSE: WAITING FOR RATES TO COME BACK TO EARTH - CLICK HERE
WALL STREET SLIDES AS TREASURY YIELDS, EARNINGS WEIGH - CLICK HERE
NASDAQ COMPOSITE: KNOCKING ON THE DOOR OF NEW HIGHS - CLICK HERE
AUTOS AND PARTS TO REMAIN UNDER PRESSURE - CLICK HERE
EUROPEAN STOCKS HAVE HIGH TRUMP PREMIUM PRICED IN - BARCLAYS CLICK HERE
EUROPE STRUGGLES FOR DIRECTION, EARNINGS MIXED - CLICK HERE
EUROPE BEFORE THE BELL: FUTURES DIP AFTER RAFT OF EARNINGS - CLICK HERE
ELECTION AND FED JITTERS GRIP MARKETS -CLICK HERE
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
